- Home
- JSPR vs ARTV Comparison
JSPR vs ARTV Comparison
Compare JSPR & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ARTV
- Stock Information
- Founded
- JSPR 2018
- ARTV 2019
- Country
- JSPR United States
- ARTV United States
- Employees
- JSPR N/A
- ARTV N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ARTV
- Sector
- JSPR Health Care
- ARTV
- Exchange
- JSPR Nasdaq
- ARTV NYSE
- Market Cap
- JSPR 321.8M
- ARTV 275.7M
- IPO Year
- JSPR N/A
- ARTV 2024
- Fundamental
- Price
- JSPR $21.53
- ARTV $10.00
- Analyst Decision
- JSPR Strong Buy
- ARTV Strong Buy
- Analyst Count
- JSPR 11
- ARTV 5
- Target Price
- JSPR $73.38
- ARTV $21.25
- AVG Volume (30 Days)
- JSPR 176.9K
- ARTV 46.2K
- Earning Date
- JSPR 11-07-2024
- ARTV 11-12-2024
- Dividend Yield
- JSPR N/A
- ARTV N/A
- EPS Growth
- JSPR N/A
- ARTV N/A
- EPS
- JSPR N/A
- ARTV N/A
- Revenue
- JSPR N/A
- ARTV $2,601,000.00
- Revenue This Year
- JSPR N/A
- ARTV N/A
- Revenue Next Year
- JSPR N/A
- ARTV N/A
- P/E Ratio
- JSPR N/A
- ARTV N/A
- Revenue Growth
- JSPR N/A
- ARTV N/A
- 52 Week Low
- JSPR $5.00
- ARTV $9.68
- 52 Week High
- JSPR $31.01
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- JSPR 48.45
- ARTV N/A
- Support Level
- JSPR $19.41
- ARTV N/A
- Resistance Level
- JSPR $23.11
- ARTV N/A
- Average True Range (ATR)
- JSPR 1.83
- ARTV 0.00
- MACD
- JSPR -0.18
- ARTV 0.00
- Stochastic Oscillator
- JSPR 31.93
- ARTV 0.00
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.